Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMC5HXI)

Drug Name
STRO-002 Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMC5HXI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Folate receptor alpha (FOLR1) TTVC37M FOLR1_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Folate receptor alpha (FOLR1) DTT FOLR1 7.262 8.091 8.377 7.459
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Ovarian cancer
ICD Disease Classification 2C73
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Folate receptor alpha (FOLR1) DTT FOLR1 1.85E-04 -1.41 -1.75
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03748186) Study of STRO-002, an Anti-Folate Receptor Alpha (FolRalpha) Antibody Drug Conjugate in Ovarian & Endometrial Cancers. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Sutro Biopharma.